Yaron Werber
Stock Analyst at TD Cowen
(0.92)
# 3,534
Out of 4,818 analysts
41
Total ratings
32.14%
Success rate
-21.22%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yaron Werber
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FBRX Forte Biosciences | Initiates: Buy | n/a | $6.86 | - | 1 | Jan 21, 2025 | |
| DNTH Dianthus Therapeutics | Initiates: Buy | n/a | $21.90 | - | 1 | Dec 20, 2024 | |
| SEPN Septerna | Initiates: Buy | n/a | $5.97 | - | 1 | Nov 19, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $160 → $153 | $159.07 | -3.82% | 5 | Nov 15, 2024 | |
| BNTX BioNTech SE | Maintains: Hold | $132 → $122 | $104.87 | +16.33% | 5 | Nov 6, 2024 | |
| UPB Upstream Bio | Initiates: Buy | n/a | $10.04 | - | 1 | Nov 5, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $61 → $73 | $35.93 | +103.20% | 2 | Oct 21, 2024 | |
| EXEL Exelixis | Maintains: Buy | $27 → $34 | $36.48 | -6.80% | 2 | Oct 21, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $54 → $59 | $29.03 | +103.24% | 1 | Jul 23, 2024 | |
| LEGN Legend Biotech | Maintains: Buy | $71 → $67 | $34.37 | +94.94% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $9.22 | - | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.37 | - | 1 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.39 | - | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $4.99 | - | 2 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $19.33 | - | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $612 → $641 | $599.86 | +6.86% | 3 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.41 | - | 1 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $25 | $0.30 | +8,233.33% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $16.77 | - | 2 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $38 | $20.25 | +87.65% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $4.37 | - | 3 | Apr 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.91 | - | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.44 | - | 1 | Oct 26, 2021 |
Forte Biosciences
Jan 21, 2025
Initiates: Buy
Price Target: n/a
Current: $6.86
Upside: -
Dianthus Therapeutics
Dec 20, 2024
Initiates: Buy
Price Target: n/a
Current: $21.90
Upside: -
Septerna
Nov 19, 2024
Initiates: Buy
Price Target: n/a
Current: $5.97
Upside: -
Ascendis Pharma
Nov 15, 2024
Maintains: Buy
Price Target: $160 → $153
Current: $159.07
Upside: -3.82%
BioNTech SE
Nov 6, 2024
Maintains: Hold
Price Target: $132 → $122
Current: $104.87
Upside: +16.33%
Upstream Bio
Nov 5, 2024
Initiates: Buy
Price Target: n/a
Current: $10.04
Upside: -
Ultragenyx Pharmaceutical
Oct 21, 2024
Maintains: Buy
Price Target: $61 → $73
Current: $35.93
Upside: +103.20%
Exelixis
Oct 21, 2024
Maintains: Buy
Price Target: $27 → $34
Current: $36.48
Upside: -6.80%
Ionis Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $54 → $59
Current: $29.03
Upside: +103.24%
Legend Biotech
Jul 15, 2024
Maintains: Buy
Price Target: $71 → $67
Current: $34.37
Upside: +94.94%
Mar 26, 2024
Upgrades: Buy
Price Target: n/a
Current: $9.22
Upside: -
Mar 18, 2024
Initiates: Outperform
Price Target: n/a
Current: $4.37
Upside: -
Mar 15, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.39
Upside: -
Jan 31, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $4.99
Upside: -
Dec 20, 2023
Initiates: Outperform
Price Target: n/a
Current: $19.33
Upside: -
Dec 12, 2023
Maintains: Outperform
Price Target: $612 → $641
Current: $599.86
Upside: +6.86%
Oct 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.41
Upside: -
Feb 28, 2023
Maintains: Market Perform
Price Target: $15 → $25
Current: $0.30
Upside: +8,233.33%
Nov 1, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $16.77
Upside: -
May 2, 2022
Initiates: Market Perform
Price Target: $38
Current: $20.25
Upside: +87.65%
Apr 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $4.37
Upside: -
Nov 30, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.91
Upside: -
Oct 26, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.44
Upside: -